Sagimet Biosciences

Update in progress

SGMT (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors for metabolic, fibrotic, and related diseases in the United States. Its lead candidate, Denifanstat, is an oral, once-daily selective FASN inhibitor studied for metabolic dysfunction-associated steatohepatitis, acne, and some cancers. TVB-3567 targets acne; other oncology programs include solid tumors and glioblastoma. Formerly 3-V Biosciences, renamed in 2019. Based in San Mateo, California.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive